Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
Titel:
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
Auteur:
Necchi, A. Pouessel, D. Leibowitz, R. Gupta, S. Fléchon, A. García-Donas, J. Bilen, M.A. Debruyne, P.R. Milowsky, M.I. Friedlander, T. Maio, M. Gilmartin, A. Li, X. Veronese, M.L. Loriot, Y.